IP Library Granted Patent US 9,441,207
Granted Patent B2
US 9,441,207 · App. 14/802,087 · Granted Sep 13, 2016

Method of replicating viruses in suspension cultures of dog kidney cells

Inventors: Monty R. Warthen (Fruitland, MD); William F. Skotta (Greenwood, DE)
Assignee: Intervet Inc.
C12N7/00C12N2760/16151C12N2760/16152C12N2760/16251C12N2760/16351
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,441,207
App. No.
14/802,087
Granted
Sep 13, 2016
Kind
B2
Abstract

Animal cells are described which can be infected by viruses and which are adapted to growth in suspension in medium free of animal-derived components, such as serum-free medium. Processes for the replication of viruses in cell culture using these cells are furthermore described, as well as vaccines which contain the viruses or antigenic portions thereof obtainable by the process.

Claims (31)

1. A method of replicating virus in a culture of sCLDK cells comprising:

a) inoculating a suspension of sCLDK cells with a virus, thereby infecting the sCLDK cells;

b) allowing said virus to reproduce in said infected sCLDK cells; and

c) harvesting said virus from said suspension culture of sCLDK cells.

2. The method of claim 1 , wherein said virus is an influenza virus.

3. The method of claim 2 , wherein said influenza virus is selected from the group consisting of a human influenza virus, an avian influenza virus, an equine influenza virus, a swine influenza virus, a canine influenza virus, and a feline influenza virus.

4. The method of claim 3 , wherein said influenza virus is an H3 influenza virus, an H5 influenza virus or an H7 influenza virus.

5. The method of claim 3 , wherein said influenza virus is selected from the group consisting of an H5N1 influenza virus, an H3N8 influenza virus, and an H3N1 influenza virus.

6. The method of claim 1 , wherein shortly before inoculating, simultaneously with inoculating, or shortly after inoculating, a protease to cleave the precursor protein of hemagglutinin is added to the suspension of sCLDK cells.

7. The method of claim 6 , wherein said protease is trypsin.

8. The method of claim 1 , wherein said culture of sCLDK cells was grown in serum-free medium.

9. The method of claim 1 , wherein said culture of sCLDK cells was grown in medium free of any animal component derived material.

10. A process of adapting substrate-dependent CLDK cells for growth in suspension comprising

a) inoculating a sample of substrate-dependent CLDK cells in a medium comprising one or more serum substitutes;

b) growing said cells in suspension in said medium;

c) serially passaging said CLDK cells in suspension in fresh batches of said medium; and

d) weaning said CLDK cells in suspension off of said one or more serum substitutes by reducing the amount of said serum substitutes in said medium to zero.

11. The process of claim 10 , wherein said medium is serum-free.

12. The process of claim 10 , wherein said medium is free of animal derived components.

13. A method of continuously propagating sCLDK cells in suspension comprising:

a) inoculating sCLDK cells into a medium;

b) growing said sCLDK cells in suspension for a period of from about 4 to 10 days;

c) transferring a sample of cultured material from (b) into fresh cell-free medium;

d) and repeating (b) and (c) for a period of continuous growth.

14. The method of claim 13 , wherein said medium is serum-free.

15. The method of claim 13 , wherein said medium is free of animal derived components.

16. The method of claim 13 , wherein said sample is transferred to said fresh cell-free medium without the prior addition of any protease.

17. The method of claim 13 , wherein the cell density after transferring the sample according to (c) is at least 3×10 5 cells/mL.

18. The method of claim 13 , wherein said sCLDK cells have a growth factor greater than about 3 over 4-10 days.

19. A sCLDK cell capable of growing in suspension obtainable by the process of adapting substrate-dependent CLDK cells for growth in suspension of claim 10 .

20. A composition comprising cell culture medium and the sCLDK cell of claim 19 .

Assignments (2)
CHANGE OF ADDRESS Recorded Sep 26, 2023
From: INTERVET INC.
To: INTERVET INC.
Reel/Frame 065028/0818 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 1, 2016
From: WARTHEN, R. MONTY; SKOTTA, WILLIAM F.
To: INTERVET INC.
Reel/Frame 039301/0057 →
Continuity (3)
Continuation 12999105
Provisional Application 61061828 · Jun 16, 2008
Related Publication 20150322411A1 · Nov 12, 2015